Lipid disorders

A continuous increase in ASCVD risk was seen with higher levels of lipoprotein(a) in the largest study to date of the relationship.

Your daily dose of the clinical news you may have missed.

Few participants with dyslipidemia received lipid-lowering medications despite high prevalence, reported authors of the Strong Family Heart Study.

Compared to the lowest intake of AS-rich food and beverages, the highest intake was associated with a 59% higher risk of developing MetS, according to new findings.

Your daily dose of the clinical news you may have missed.

Cardiovascular mortality has been increasing among middle-aged US adult since 2011; a new study looked at changes in CV risk factors by income level over the past 20 years.

Excess CVD mortality among Black vs White adults was diminished after control for behavior/metabolic factors and negligible after adjustments for SDOH, a new study reveals.

A daily dose of clinical news on Patient Care you may have missed.

Reductions in LDL-C, HbA1c, and body weight were associated with a variety of vegetarian diets in participants with or at high risk for cardiovascular disease.

Your daily dose of clinical news you may have missed.

For the 1 in 3 individuals with hyperlipidemia who can't or won't take a statin, preventive cardiologist Elizabeth Klodas, MD, details 3 alternative drug classes.

Preventive cardiologist Elizabeth Klodas, MD, reviews the essential elements of a plan of eating shown clinically to reduce hyperlipidemia.

In Israel, where 60% of adults are overweight, new research prompts investigators to suggest that % body fat should replace BMI as the gold standard measure of obesity.

In a recent comparison of guideline recommendations for initiating statin therapy in primary prevention, researchers found significant differences in the numbers who would benefit.

Your daily dose of clinical news you may have missed.

ADA 2023: The only nonstatin therapy to reduce risk for 4-point MACE in ASCVD may potentially find a role in primary prevention as well, though caution is advised.

Colchicine 0.5 mg is associated with reduction in a wide range of CV events in patients already on statin therapy, supporting the long-held "anti-inflammatory" hypothesis.

Your daily dose of clinical news you may have missed.

ENDO 2023: Treatment with bempedoic acid was found comparable to statin therapy in an analysis of the CLEAR Outcomes trial based on CTT Collaboration methodology.

High salt intake linked to coronary atherosclerosis; daily ETOH, even in small doses, is dangerous; statins don't increase muscle injury; and 2 more studies of note.

Each 1000 mg rise in Na excretion saw a corresponding 3%, 4%, and 4% higher risk of worsening carotid plaque, CAC score, and coronary artery stenosis, respectively.

Your daily dose of clinical news you may have missed.

A daily dose of clinical news you may have missed.

Analysis of NHANES data between 2013-2020 found statin use low across racial/ethnic groups and significantly lower among Black and Hispanic participants.

Each of the quotes is taken from a study reviewed on Patient Care during the week and was chosen for the research team’s passion about the clinical implications of their findings.

Your daily dose of clinical news you may have missed.

Among patients in the highest quartile of hsCRP, the risks of CV-related and all-cause death were more than 2 times higher than in those in the highest quartile of LDL-C.

ACC2023. For high-risk T2D patients not receiving optimal treatment for hyperlipidemia, hypertension, or hyperglycemia, intensive, multidisciplinary training for clinic staff could shift practice.

A statin tops the list of most commonly prescribed Medicare drugs in most states. But in Alabama, it's Vicoodin, and the number of prescriptions written there exceeds the other 49 states.

Worldwide the report finds that hypertension, hypercholesterolemia, dietary risks, and air pollution are the leading causes of CVD which remains the leading cause of death globally.